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Abstract
Introduction: We have previously described the labeling of interleukin-2 (IL2) with
123I and
99mTc-
N3S. Both radiopharmaceuticals were successfully applied in humans to image several
inflammatory lesions and autoimmune diseases characterized by tissue infiltrating lymphocytes
expressing the IL2 receptor (CD25). However, both radiopharmaceuticals had some specific
disadvantages, such as cost and time of synthesis.
Materials and methods: Here, we describe a new improved method for labeling interleukin-2 with
99mTc using HYNIC-NHS and tricine as coligand. Several optimizations of reagent concen-
trations and labeling conditions were performed in order to standardize the procedure. After
labeling, IL2 was purified by tC2 reverse-phase chromatography and tested in vitro and in vivo,
in mice and in a normal volunteer. Results showed that this labeling procedure is cheap, fast,
reliable, and reproducible, leading to a product with high specific activity (153 µCi/µg), high
stability and capable of binding in vitro to CD25 positive cells. In vivo biodistribution in mice and
human volunteer did not show any significant different from
99mTc-N3S-IL2.
Conclusion: In conclusion, the optimization of
99mTc-HYNIC-IL2 has a great advantage in terms
of cost and time of production and a simple kit formulation can be considered for routine
application to study patients affected by autoimmune diseases, graft rejection, or other chronic
inflammatory disorders.
Key words: Interleukin-2, Inflammation, Radiopharmacy, Molecular imaging
Introduction
I
nterleukin-2 is a small single-chain glycoprotein
(15.5 kDa) of 133 amino acids that is synthesized and
secreted in vivo by activated lymphocytes in several
pathological conditions, such as autoimmune diseases, graft
rejection, and tumors characterized by chronic infiltration of
lymphomononuclear cells expressing the IL2R (interleukin-2
receptor) on their surface membrane.
The IL2R is formed by three proteins α, β and γ chain,
namely the CD25, CD122, CD132. The high affinity
receptor is the ethero-trimer, although also CD25 and
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[1]. The identification of these cells in vivo has important
diagnostic, prognostic, and therapeutic implications. IL2
radiolabeled with
123I and
99mTc has been proven to be
useful to target-activated lymphocytes expressing CD25
molecule (interleukin-2 receptor) in chronic inflammatory
diseases, such as coeliac disease [2], Crohn's disease [3],
type 1 diabetes [4], Hashimoto's thyroiditis, Sjogren syn-
drome, cutaneous melanoma [5] and head and neck
carcinoma [6]. These clinical studies have demonstrated the
efficacy of using scintigraphy to detect activated lympho-
cytes, which correlate with the severity of tissue lympho-
cytic infiltration and that scintigraphy with radiolabeled IL2
can be used for monitoring the efficacy of specific therapies.
Until now, Interleukin-2 (Proleukin®, Aldesleukin®) has
routinely been labeled in our institution with
123I, but the cost
and time of production requiring HPLC purification of final
product, has limited its use to a proof of concept. We then
labeled IL2 with
99mTc by means of a two-step approach
based on the use of N3S ligand as bifunctional chelating
agent. This synthetic approach yields
99mTc-labeled IL2 with
high specific activity [7]. However, the whole process is a
multi-step procedure that requires post-labeling purification
and takes approximately three hours of work. This greatly
limits its routine clinical application. The aim of this work
was to develop and optimize a single-step radiolabeling
procedure of IL-2 (Proleukin®) based on the pre-conjugation
of the protein with succinimidyl-6-hydrazinopyridine-3-
carboxilate (HYNIC-NHS) as a bifunctional chelating agent
and tricine as coligand, based on the fact that combination of
HYNIC-peptide with tricine produces a ternary ligand system
which forms a stable technetium complex. This procedure
could potentially be used to obtain a kit formulation available
for routine clinical use without post-labeling purification. The
biological activity of the new complex was also assessed in
comparison with the radiopharmaceutical previously used.
Materials and Methods
Conjugation of IL-2 with HYNIC-NHS
Recombinant human Interleukin-2 (Aldesleukin®) was provided by
Chiron (Novartis, Italy) as a freeze-dried powder. The heterobifunc-
tional linker succinimidyl-6-hydrazinopyridine-3-carboxylate
(HYNIC-NHS) was purchased from Solulink (USA) and conju-
gated to the IL2 as previously described by Abrams et al. [8] with
slight modifications. Briefly, IL2 was reconstituted with nitrogen-
purged water for injection to a concentration of 2.4 mg/ml. A molar
excess of HYNIC-NHS ranging from 3:1 to 12:1 in dimethylfor-
mamide (DMF, Sigma-Aldrich Chemical) was then added dropwise
to 100 µl of the IL2 solution and 100 µl buffer solution. Three
different buffer solutions were also explored to assess the effect of
pH of conjugation on labeling efficiency, as described. After
stirring gently for 2 h in darkness at room temperature, the HYNIC-
IL2 complex was purified by solid-phase extraction chromatog-
raphy (SPE). To eliminate the excess of unbound HYNIC-NHS, the
reaction mixture was passed through a tC2 Sep-Pak® Cartridge
(Waters Corporation, USA) and the product was eluted with a step-
gradient of H2O/acidified ethanol (25% phosphoric acid/ethanol 2/
98). The eluate was divided into 15-µg aliquots and stored in liquid
nitrogen for future use. The HYNIC-IL2 conjugate was analyzed by
high-performance liquid chromatography (HPLC) using a C18
reverse-phase column Inertsil ODS 2 (Phenomenex, 4.6 mm×
25 mm) by simultaneously monitoring of UV absorbance (at
280 nm) and activity, at a flow rate 1.0 ml/min using 0.1% TFA/
water (solvent A) and 0.1% TFA/acetonitrile (solvent B). The
gradient started at 10% solvent B for 5 min, changed to 70%
solvent B over 10 min, held constant for 5 min, changed to 90%
solvent B over 5 min and finally back to 10% solvent B over 2 min.
The average number of hydrazino groups incorporated in each
molecule was spectrophotometrically determined by converting the
hydrazino group into a hydrazone moiety. Briefly, 100 μl of the
conjugated IL2 was diluted in 1 mL of O-sulfonic benzaldehyde
(Fluka, 0.1 M sodium acetate pH 4.7) and incubated in the dark
overnight at room temperature. The conversion of hydrazino groups
to the corresponding hydrazones was quantified by measurement of
the optical density at 343 nm using a calibration curve [8].
Protein Characterization by Matrix-Assisted Laser
Desorption Ionization Time-of-Flight
To characterize the modification occurred during the conjugation
and to determine how the pH of the reaction can influence the
incorporation of HYNIC-NHS molecule to IL2, a Matrix-assisted
laser desorption ionization time-of-flight (MALDI-ToF) mass
spectrometric determination was performed. A volume of 10 µL
of HYNIC-IL2 complex (prepared at different pH values as
previously described) was diluted 1:10 with 3,5-dimethoxy-4-
hydroxycinnamic acid matrix solution (10 mg/ml in 50% acetoni-
trile/1%TFA, Sigma) to a concentration of about 10 pmol/µl. An
aliquot (1–2 µl) of the final solution was applied to the sample
target prior to insertion into the high vacuum of the mass
spectrometer Voyager-De MALDI-ToF (Applied Biosystems).
MALDI-ToF operation conditions were set as follow: mode of
operation was linear, polarity was positive, the acceleration voltage
was 20,000 V, delayed extraction time was 100 ns and the
acquisition mass range was 14,000–17,000 Da.
Radiolabeling of HYNIC-IL2 Conjugate
The HYNIC-IL2 conjugate was radiolabeled with
99mTc by adding
1 μl of tricine (100 mg/ml in 1 M sodium acetate buffer, Sigma-
Aldrich) used as a coligand, 0.1–0.2 ml of freshly eluted
99mTcO4
−
solution (1–10 mCi, 37–370 MBq) and 10 µl of SnCl2 solution
(2 mg/ml in nitrogen-purged 0.1 M HCl, Sigma-Aldrich) to 100 µl
of HYNIC-IL2 (15 µg). The reaction mixture was incubated for
30 min at room temperature. To evaluate the non-specific binding
of technetium to IL2, unconjugated IL-2 was labeled using the
same conditions. All the preparations were analyzed using instant
thin-layer chromatography-silica gel (ITLC-SG, Pall Corporation).
Thus, chromatographic strips were performed by spotting 2.5 µl of
the radiolabeled complex on the strip and developed either with
0.9% NaCl, for the determination of the labeling efficiency (LE),
or with acetone, as the mobile phase, for determination of the
percentage of free
99mTcO4. The percentage of insoluble and
“colloidal” species were also identified by ITLC, using albumin-
soaked ITLC-SG strips using a mobile phase of EtOH:NH4:H2O
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System). The
99mTc-HYNIC-IL2 complex was purified by SPE
using a tC2 Sep-Pak® Cartridge (Water Corporation) using a step-
gradient of H2O/acidified ethanol (25% phosphoric acid/ethanol
2/98), in order to remove the excess of free
99mTc-pertechnetate and
uncoupled
99mTc-Tricine. Interleukin-2 (1 mg/ml) was also labeled
using the method previously described by Chianelli et al.[ 7]i n
order to compare its biological activity with that of the new
HYNIC-IL2 complex.
Optimization of the Radiolabeling Procedure
Influence of Conjugation Conditions on LE of HYNIC-IL2
Complex In order to optimize the conjugation conditions and
consequently to achieve the highest labeling efficiency, different
molar ratios of HYNIC-NHS:IL2 ranging from 3:1 to 12:1 and
several buffer systems were tested. Due to the limited stability of
IL2 at pH97.0 for a long time during the conjugation, the optimum
pH value was assessed by performing the conjugation in presence
of an excess of HYNIC-NHS ranging between 3:1 to 12:1 and
using the following buffer solutions (100 µl): 100 mM phosphate
with 150 mM NaCl buffer solution pH 7.2; 1.0 M NaHCO3,p H
8.5; and 1.0 M Na2CO3/NaHCO3, pH 9.2. After 30 min of reaction,
the resulting HYNIC-IL2 complex was purified by solid-phase
extraction chromatography and preparations were labeled with
99mTc-pertechnetate and analyzed by instant thin-layer chromatogra-
phy-silica gel (ITLC-SG) chromatographic strips, as described above.
Influence of Labeling Conditions on LE of HYNIC-IL2
Complex The effects of variation in the labeling conditions on
radiolabeling efficiency and the levels of technetium colloids as
well as soluble
99mTc-labeled impurities produced were explored.
pH values ranging from 4 to 7 and tricine:IL2 ratios ranging from
14000 to 1000 were studied. All the preparation were analyzed
using instant thin-layer chromatography-silica gel (ITLC-SG)
chromatographic strips for the determination of the LE, % colloids
and free technetium using saline, EtOH:NH4:H2O (2:1:5) and
acetone, respectively, as solvent as described above.
Stability of
99mTc-HYNIC-IL2
The stability of
99mTc-HYNIC-IL2 was evaluated by incubating
100 µl of
99mTc-HYNIC-IL2 in 900 µl of either human serum or
saline for 24 h at 37°C. The percentage of intact
99mTc-HYNIC-IL2
was analyzed by ITLC-SG using saline as the mobile phase. The
stability of
99mTc-HYNIC-IL2 was also evaluated in the presence
of increasing amounts of DTPA, with molar ratios ranging from 1:1
to 1000:1 DTPA:
99mTc-HYNIC-IL2.
SDS-PAGE of
99mTc-HYNIC-IL2
The effect of modifications to integrity of the IL2 molecule during
conjugation, SPE purification and labeling reaction were tested by
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) performed under non-reducing condition. Electrophoresis
of recombinant IL2 (Aldesleukin®, Chiron), HYNIC-IL2 and
99mTc-HYNIC-IL2 (before and after purification) was performed
using a 10-15% gradient SDS-PAGE on a PHAST system
(Amersham-Pharmacia).
In vitro Evaluation of Biological Activity
of the HYNIC-IL2 Complex
The biological activity of IL2 after conjugation with HYNIC-NHS
was assessed by performing a proliferation assay using the IL2-
dependent cytotoxic T-cell line CTLL-2, (ATCC, USA). CTLL-2 is
a subclone of cytotoxic T lymphocytes from the mouse strain
C57BL/6. The proliferation of CTLL-2 cells in the presence of
serial dilutions of modified-IL2 or unmodified-IL2 was evaluated
by the MTT proliferation assay. Dilutions of IL2 (native, HYNIC-
conjugated and N3S-conjugated) were made in RPMI 1640 medium
supplemented with 100 UI/ml penicillin, 100 µg/ml streptomycin
and 2 mM L-glutamine (all from Gibco Life Technologies, Roskilde,
Denmark). MTT (3-[4,5-dimethylthiazolyl-2]-2,5-diphenyl tetrazo-
lium bromide; Sigma-Aldrich) was diluted to 5 mg/ml in sterile
phosphate-buffered saline solution (PBS, pH 7.4) and filtered once
through a 45-µm filter. The diluted MTT was kept protected from
light at 4°C and used within a month.
CTLL-2 Cell Line and Culture Conditions The IL2 dependent
cell line CTLL-2 was cultured continuously and maintained at a
concentration of 1–5×10
5 cells/ml in RPMI 1640 medium supple-
mentedwith100UI/mlpenicillin,100µg/mlstreptomycinand2mM
L-glutamine (all from Gibco, Denmark), 10% heat-inactivated fetal
calf serum (Gibco, Denmark), 1 mM sodium pyruvate (Gibco,
Denmark), 25 mM HEPES (Gibco Denmark, pH 7.4), and 5.5×10
−5
M beta-mercaptoethanol (Sigma-Aldrich). The cells were main-
tained in presence of a low concentration of recombinant human IL2
(10 UI/ml, Chiron, Novartis, Italy) at 37°C in 5% CO2 atmosphere
for 24–48 h.Threedays before use,thecells werewashedthree times
in IL2-free culture medium by centrifugation for 7 min at 1,200 rpm
to allow internalization of any IL2 bound to its receptors and then
adjusted to1×10
6cells/ml. Theculturemedium wasrefreshed for the
last time 24 h before the bioassay and cultured without IL2.
MTT Assay CTLL-2 cells were harvested and washed with
complete medium three times then resuspended in RPMI complete
medium at 5×10
5cells/ml. CTLL-2 was pipetted into a 96-well plate
(100 µl, 5×10
4cells/well) containing 100 µl of serially diluted
solutions of native IL2, HYNIC-conjugated and N3S-conjugated IL2
(from 0 to 1,000 UI/ml) and incubated at 37°C in 5% CO2 for 24 h.
After 24 h the diluted MTT in PBS pH 7.4 (5 mg/ml) was added at
20µl/well.After4hofincubation,50µl/wellofsolubilizationsolution
containing 50% dimethylformamide and 10% sodium dodecyl sulfate
in 0.1 M HCl (DMF/SDS, pH 4.7) was added and left to incubate
overnight to dissolve the reduced MTT crystals. The absorbance was
measured with a microplate reader (BioRad, Model 550) at a test
wavelength of 570 nm and a reference wavelength of 620 nm (to read
the MTT formazan and the unconverted MTT, respectively).
Studies in Animals
The biodistribution of
99mTc-IL2 was studied in 9 normal Balb/c
mice injected i.v. with
99mTc-IL2 (approx. 3.7 MBq). Animals were
killed after 30 (n=3), 60 (n=3), or 120 min (n=3). Major organs
C. D’Alessandria, et al.: Labeling of
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and counted in a single well gamma counter, together with samples
of serial dilutions of the injected
99mTc-IL2 (1:100, 1:1,000,
1:10,000, 1:100,000). Results were expressed as percentage of the
injected dose per gram of tissue±standard deviation (SD).
Biodistribution in a Normal Volunteer
Radiolabeled
99mTc-IL2 was sterilized by filtration through a
0.22 µm Millipore filter (low protein-binding filter, pre-loaded with
human serum albumin) into a sterile vial containing 5 ml of 5%
glucose solution and 0.3% human serum albumin. In order to
compare the biodistribution of
99mTc-HYNIC-IL2 in humans with
that of
99mTc-N3S-IL2, we administered intravenously 111 MBq
(3 mCi, about 20 µg) of
99mTc-HYNIC-IL2 to a healthy normal
volunteer after written informed consent. Anterior and posterior total
body imageswereacquiredat30 min,1h,2h,and 3hafterinjection.
Results
Conjugation of IL2 with HYNIC-NHS
Optimum conjugation was obtained by incubating IL2 with
HYNIC-NHS for 2 h in darkness using a 12:1 HYNIC/IL2
molar ratio. Under these conditions, a stable HYNIC/IL2
conjugate was obtained with a mean number of 1.2 molecules
of HYNIC per molecule of IL2 incorporated, as determined
by the hydrazine assay. Extending the conjugation time
beyond 2 h did not result in an increase in stability or labeling
efficiency. The bicarbonate buffer system produced the best
conjugation yield. These conjugation conditions (bicarbonate
buffer, HYNIC/IL2 12:1, 2 h incubation time) were used for
all further in vitro and in vivo experiments.
Protein Characterization by MALDI-ToF
MALDI-ToF analysis was used to determine the effect of pH
on the number of HYNIC molecules attached to IL2 (Fig. 1).
The degree of conjugation is greater at pH 8.5 than pH 7.2 or
pH 9. The mass spectra of HYNIC-IL2 conjugated at pH 8.5
Fig. 1. Characterization of HYNIC-IL2 by MALDI-ToF. The
conjugation at pH 8.5 (b) results in a higher conjugation yield
and a mean mass value of 15,600 Da for the HYNIC-IL2
complex than pH 7.4 (a) or pH 9.2 (c).
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Fig. 2. Effect of the HYNIC to IL2 ratio (upper panel) and the
pH of conjugation (bottom panel) on labeling efficiency of the
HYNIC-IL2 complex.
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99mTc-Hynic-Interleukin-2shows that about 50% of the IL2 molecules remain
unconjugated (MWt: 15,330 Da), while the majority of the
remainder carry one molecule of HYNIC-NHS (15,550 Da)
and a smaller proportion two molecules (15,780 Da).
Optimization of Radiolabeling of HYNIC-IL2
Conjugate
Influence of Conjugation Conditions on LE of HYNIC-IL2
Complex
99mTc-HYNIC-IL2 labeling efficiency achieved
was dependent on the molar ratio of HYNIC:IL2 and on the
conjugation pH. A labeling efficiency of >90% was obtained
when a molar ratio of 12:1 and a pH of 8.5 were used for the
conjugation (Fig. 2) but LE ranged between 25% and 70%
when lower conjugation ratios or other pH’s were used. Best
results in terms of conjugation yields were obtained at an
IL2 concentration of 2.4 mg/ml, while lower yields were
obtained when the IL2 concentration was 1.4 mg/ml or
4.8 mg/ml (data not shown). The IL2 conjugate purified by
tC2 Sep-Pak cartridge and stored in liquid nitrogen showed a
good stability for at least 30 days.
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Fig. 5. Analysis of
99mTc-HYNIC-IL2 stability in human
serum, saline, and DTPA solution after purification by tC2
Sep-Pak.
Fig. 4. Chemical characterization of
99mTc-HYNIC-IL2 by
reverse-phase HPLC. Both, the radiochromatogram (elution
profile a) and the UV chromatogram (elution profile b) are
presented. The peak at 18.013 min showed all the activity
bound to
99mTc-HYNIC-IL2 and corresponds to the UV peak
for HYNIC-IL2. In the UV profile, the peak at 37.418 min is
due to a dimerization of HYNIC-IL2 that may occur because
of the HPLC running buffer in which IL2 was diluted, with no
corresponding radioactive peak. The peak eluted at early
time in the radioactive profile is due to a little percentage of
free
99mTc-tricine.
Fig. 6. SDS-PAGE of
99mTc-IL2 performed in non-reducing
conditions. Lanes 1–4 showed the unconjugated-IL2 (lane 1),
the HYNIC-IL2 complex after tC2 purification (lane 2), radio-
labeled IL2 before (lane 3) and after purification with tC2
cartridge (lane 4). Dimers, trimers, and
99mTc-HYNIC-IL2
aggregates are absent.
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Complex Best labeling results were obtained at pH 5.5 (see
Fig. 3). At either pH 4 or 7 a greater percentage of technetium
colloids and soluble impurities (pertechnetate and
99mTc-
tricine) were produced. Reducing the tricine concentration
from an excess of 14,000 to 1,000 also improved the labeling
efficiencyandallowedagreaterspecificactivitytobeachieved.
The maximum labeling efficiency for the HYNIC-IL2
complex (>95%) was therefore obtained by the conjugation
at pH 8.5 with a HYNIC:IL2 ratio of 12:1 and the labeling
reaction in sodium acetate buffer pH 5.5 with a tricine:IL2
ratio of 1,000. This labeling efficiency was achieved before
SPE purification. After tC2 Sep-Pak cartridge purification, a
radiochemical purity of
99mTc-HYNIC-IL2 of around 99%
was routinely achieved. These results were confirmed by
HPLC analysis (Fig. 4).
99mTc-HYNIC-IL2 Stability in Human Serum
and Saline
Stability studies showed a loss of only 6% in purity when
99mTc-HYNIC-IL2 was incubated for 6 h in saline at 37°C.
No detectable loss in purity was observed, during 20 h of
incubation at 37°C in human serum, even when challenged
with an excess of DTPA (Fig. 5).
SDS-PAGE of
99mTc-HYNIC-IL2
The evaluation of the integrity of IL2 was evaluated by
SDS-PAGE as a result of the conjugation, radiolabeling, and
purification procedures (Fig. 6). The reduction in intensity of
the band in track 4 is a result of the dilution effect occurred
during purification.
In vitro Biological Activity of HYNIC-IL2
Complex
The ability of
99mTc-HYNIC-IL2 to stimulate cell prolifer-
ation was evaluated on CTLL-2 by incubation of cells at
increasing concentrations of unconjugated, HYNIC-conju-
gated, or N3S-conjugated IL2. No significant difference in
the levels of stimulation by the different preparations was
observed (Fig. 7).
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Fig. 7. Evaluation of biological activity of HYNIC-IL2 on CTLL-2 cells by MTT assay. The maximum in the proliferation was
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The biodistribution of
99mTc-IL2 in Balb/c mice showed that
the kidneys were (as expected) the major organs of uptake
(50%) of the radiotracer at both time points studied. Liver
and spleen also showed a significant uptake of
99mTc-IL2.
There was negligible uptake in the lungs and circulating
radioactivity was rapidly cleared (data not shown).
Biodistribution in a Normal Volunteer
The biodistribution of
99mTc-HYNIC-IL2 in the normal
volunteer was very similar to that seen with
99mTc-N3S-IL2
andshowedfastplasmaclearancewithkidneysbeingthemajor
organs of accumulation; the kidney uptake increased up to 1 h
and declined thereafter. Liver and spleen were also detectable.
No significant excretion in the bowel was observed and no
uptake inthe thyroidor any other organ was observedup to3 h
post-injection (Fig. 8). No adverse effects were observed.
Discussion
The study of lymphocyte migration in chronic inflammation is
an attractive targetformolecular nuclearmedicineforimaging
chronic lymphocyte-mediated inflammation [9]. In particular,
imaging with radiopharmaceuticals that bind to lymphocytes
could be usefulforthe evaluation of diseaseactivity in chronic
inflammatory disorders, allowing selection of the best ther-
apeutic option and follow-up of its efficacy [10]. To this end,
we have routinely used technetium-labeled IL2 for the in vivo
diagnosis of chronic inflammation, and, in particular, to
evaluate the severity and extent of organ-specific autoimmune
diseases and to detect peri-tumoral lymphocytic infiltration
[5]. Although radiolabeled IL2 is a valuable radiopharmaceut-
ical for diagnostic purposes, the previously described labeling
procedure remains tedious, expensive, and time consuming
owing to the poor solubility and stability of this cytokine.
The aim of this study was to characterize and optimize
the conjugation of HYNIC-NHS to interleukin-2 in order to
obtain a more readily available and stable conjugate that is
useful for radiolabeling with
99mTc in a single-step labeling
procedure. The effect of conjugation conditions on bio-
logical activity of the IL2 was studied. The effect of the pH
of conjugation reaction and the HYNIC-NHS to IL2 molar
ratio on HYNIC substitution and labeling efficiency were
also investigated. Higher HYNIC-NHS-to-IL2 conjugation
ratios resulted in increased conjugation yield, but could also
lead to the formation of higher molecular weight aggregates
andeventoprecipitation.AconcentrationofIL2of2.4mg/ml
resulted in efficient conjugation, but a higher concentration
resulted in protein aggregation and precipitation due to the
poor solubility of the protein in water after reconstitution of
the powder. A 12-fold molar excess of HYNIC-NHS was
required to incorporate a mean number of 1.2 molecules of
ligand per IL2 molecule without aggregation or loss of
biological activity. Although the bicarbonate buffer used for
the conjugation is not very stable, the use of this buffer
improved the conjugation yield and consequently the labeling
Fig. 8. Anterior and posterior images of the abdomen acquired at 30 min, 1 h, 2 h and 3 h, after i.v. bolus injection of 185 MBq
of
99mTc-HYNIC-IL2. Images are comparable to those obtained with
99mTc-N3S-IL2 and show no bowel excretion of
radioactivity, with the kidney being the major catabolic organ. Faint spleen uptake can be observed due to the high number of
IL2R +ve cells in this organ.
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labeling efficiency achieved for
99mTc-HYNIC-IL2 was
always >90%.
A radiolabeling pH of 5.5 was necessary to achieve the
highest labeling efficiency with no colloid or
99mTc
impurities. Best tricine:IL2 ratio was 1,000:1 resulting in
an increase in the specific activity up to 4 kBq/μg. No
irreversible aggregation or fragmentation of the IL2 mole-
cule occurred during conjugation, labeling, and purification
as was shown by SDS-PAGE. In the MTT assay, the
conjugate-IL2 was shown to retain its ability to interact with
the IL2 receptors on the surface of the CTLL-2 cells and to
promote their proliferation. The biological activity of
HYNIC-IL2 was also compared with that of N3S-IL2, which
was previously used as an imaging probe. A difference of
less than 10% in proliferation induction was found between
the two conjugates.
In conclusion, we have optimized and described the
synthesis of a stable HYNIC-IL2 complex, which can be
radiolabeled in high yields with
99mTc. The
99mTc-HYNIC-
IL2 conjugate can be obtained with high specific activity and
retained receptor binding ability. Biodistribution in mice and
normal human volunteer was not different from that of the
previously published
99mTc-N3S-IL2. This newly synthesized
99mTc-HYNIC-IL2 can be prepared much easier and more
reproducible than
99mTc-N3S-IL2 and could, in the future, be
a promising radiopharmaceutical to investigate lymphocytes
migration in man affected by chronic inflammatory disease.
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